373 related articles for article (PubMed ID: 34789066)
1. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
3. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
4. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
6. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
8. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R;
Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
11. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
12. Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population.
Gupta A; Hussain SM; Sonthwal N; Chaturvedi H
J Cancer Res Ther; 2021; 17(2):389-392. PubMed ID: 34121682
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G; Sayegh N; Thomas VM; Chigarira B; Tripathi N; Jo YJ; Li H; Sahu KK; Srivastava A; McFarland T; Maughan BL; Swami U; Agarwal N
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):279-282. PubMed ID: 37460732
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
15. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
16. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
19. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with
Park DJ; Kwon TG; Park JY; Joung JY; Ha HK; Jeon SS; Hong SH; Park S; Lee SH; Cho JS; Park SW; Kwon SY; Jo JK; Park HS; Lee SC; Kwon DD; Kim SI; Park SH; Kim S; Jeong CW; Kwak C; Choi SH;
World J Mens Health; 2024 Jan; ():. PubMed ID: 38164028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]